RaQualia Pharma Inc. (TYO:4579)
Japan · Delayed Price · Currency is JPY 463.00
-13.00 (-2.73%)
Jun 24, 2026, 2:05 PM JST
RaQualia Pharma Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,817 | 3,979 | 3,107 | 1,901 | 2,918 | 2,776 | |
Revenue Growth (YoY) | 11.45% | 28.07% | 63.44% | -34.85% | 5.12% | 150.77% |
Cost of Revenue | 670.51 | 712 | 625 | 245 | 231 | 321 |
Gross Profit | 3,146 | 3,267 | 2,482 | 1,656 | 2,687 | 2,455 |
Selling, General & Admin | 1,224 | 893 | 782 | 615 | 566 | 615 |
Research & Development | 1,692 | 1,599 | 1,703 | 1,372 | 1,248 | 1,127 |
Amortization of Goodwill & Intangibles | - | 285 | 203 | - | - | - |
Operating Expenses | 2,916 | 2,784 | 2,695 | 1,993 | 1,820 | 1,747 |
Operating Income | 230.41 | 483 | -213 | -337 | 867 | 708 |
Interest Expense | -59.74 | -59 | -42 | -7 | -6 | -1 |
Interest & Investment Income | 38.34 | 26 | 8 | 9 | 13 | 22 |
Currency Exchange Gain (Loss) | 54.94 | -40 | 38 | 52 | 43 | 145 |
Other Non Operating Income (Expenses) | -13.95 | 1 | -130 | 11 | -17 | -1 |
EBT Excluding Unusual Items | 250.01 | 411 | -339 | -272 | 900 | 873 |
Gain (Loss) on Sale of Investments | - | - | 4 | - | -35 | 16 |
Asset Writedown | - | 26 | -23 | -22 | 3 | -10 |
Other Unusual Items | - | - | - | - | -18 | - |
Pretax Income | 250.01 | 437 | -358 | -294 | 850 | 879 |
Income Tax Expense | 197.37 | 164 | 137 | 29 | 127 | 124 |
Net Income | 52.64 | 273 | -495 | -323 | 723 | 755 |
Net Income to Common | 52.64 | 273 | -495 | -323 | 723 | 755 |
Net Income Growth | - | - | - | - | -4.24% | - |
Shares Outstanding (Basic) | 24 | 24 | 22 | 22 | 21 | 21 |
Shares Outstanding (Diluted) | 24 | 24 | 22 | 22 | 21 | 21 |
Shares Change (YoY) | 12.74% | 11.14% | 0.16% | 2.97% | 0.05% | 0.10% |
EPS (Basic) | 2.15 | 11.52 | -22.87 | -14.95 | 34.48 | 36.03 |
EPS (Diluted) | 2.15 | 11.36 | -22.87 | -14.95 | 34.47 | 36.03 |
EPS Growth | - | - | - | - | -4.34% | - |
Free Cash Flow | 137.01 | -421 | 84 | -923 | 1,449 | 274 |
Free Cash Flow Per Share | 5.60 | -17.50 | 3.88 | -42.72 | 69.06 | 13.06 |
Gross Margin | 82.43% | 82.11% | 79.88% | 87.11% | 92.08% | 88.44% |
Operating Margin | 6.04% | 12.14% | -6.86% | -17.73% | 29.71% | 25.50% |
Profit Margin | 1.38% | 6.86% | -15.93% | -16.99% | 24.78% | 27.20% |
Free Cash Flow Margin | 3.59% | -10.58% | 2.70% | -48.55% | 49.66% | 9.87% |
EBITDA | 712.12 | 970 | 188 | -162 | 1,014 | 849 |
EBITDA Margin | 18.66% | 24.38% | 6.05% | -8.52% | 34.75% | 30.58% |
D&A For EBITDA | 481.71 | 487 | 401 | 175 | 147 | 141 |
EBIT | 230.41 | 483 | -213 | -337 | 867 | 708 |
EBIT Margin | 6.04% | 12.14% | -6.86% | -17.73% | 29.71% | 25.50% |
Effective Tax Rate | 78.95% | 37.53% | - | - | 14.94% | 14.11% |